Yazdanpanah Y - Search Results

1

Endocarditis due to gram-negative bacilli at a French teaching hospital over a 6-year period: clinical characteristics and outcome.

Loubet P, Lescure FX, Lepage L, Kirsch M, Armand-Lefevre L, Bouadma L, Lariven S, Duval X, Yazdanpanah Y, Joly V. Loubet P, et al. Among authors: yazdanpanah y. Infect Dis (Lond). 2015;47(12):889-95. doi: 10.3109/23744235.2015.1075660. Epub 2015 Aug 11. Infect Dis (Lond). 2015. PMID: 26260729

2

CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.

Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X; FHDH-ANRS CO4 Epidemiology Group. Guiguet M, et al. Among authors: yazdanpanah y. Antivir Ther. 2009;14(3):451-7. doi: 10.1177/135965350901400311. Antivir Ther. 2009. PMID: 19474479

3

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group. Charpentier C, et al. J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14. J Antimicrob Chemother. 2013. PMID: 23152480 Clinical Trial.

4

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Among authors: yazdanpanah y. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.

5

Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y. Charpentier C, et al. Among authors: yazdanpanah y. PLoS One. 2013;8(3):e59205. doi: 10.1371/journal.pone.0059205. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527135 Free PMC article.

6

Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs.

Birgand G, Ruimy R, Schwarzinger M, Lolom I, Bendjelloul G, Houhou N, Armand-Lefevre L, Andremont A, Yazdanpanah Y, Lucet JC. Birgand G, et al. Among authors: yazdanpanah y. Antimicrob Resist Infect Control. 2013 Nov 4;2(1):30. doi: 10.1186/2047-2994-2-30. Antimicrob Resist Infect Control. 2013. PMID: 24180674 Free PMC article.

7

Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia.

Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D. Loubet P, et al. Among authors: yazdanpanah y. AIDS Res Hum Retroviruses. 2014 Sep;30(9):863-6. doi: 10.1089/AID.2014.0089. Epub 2014 Jul 14. AIDS Res Hum Retroviruses. 2014. PMID: 24946849

8

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay.

Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R. Charpentier C, et al. Among authors: yazdanpanah y. J Antimicrob Chemother. 2014 Oct;69(10):2819-25. doi: 10.1093/jac/dku211. Epub 2014 Jun 19. J Antimicrob Chemother. 2014. PMID: 24948705

9

Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report.

Nguyen LB, Harent S, Peytavin G, Visseaux B, Bastard JP, Dubourg O, Lariven S, Patrick Yeni, Yazdanpanah Y, Lescure FX. Nguyen LB, et al. Among authors: yazdanpanah y. AIDS. 2014 Aug 24;28(13):1995-7. doi: 10.1097/QAD.0000000000000387. AIDS. 2014. PMID: 25259710 No abstract available.

10

Prolonged hospital stay, an adverse effect of strict national policy for controlling the spread of highly resistant microorganisms.

Birgand G, Schwarzinger M, Perozziello A, Lolom I, Pelat C, Armand-Lefevre L, Buzzi JC, Andremont A, Yazdanpanah Y, Lucet JC. Birgand G, et al. Among authors: yazdanpanah y. Infect Control Hosp Epidemiol. 2014 Nov;35(11):1427-9. doi: 10.1086/678425. Epub 2014 Oct 2. Infect Control Hosp Epidemiol. 2014. PMID: 25333442 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

723 results

Search Page